High-dose benzodiazepine (BZD) dependence represents an emerging and under-reported addiction phenomenon and is associated with reduced quality of life. To date there are no guidelines for the treatment of high-dose BZD withdrawal. Low-dose slow flumazenil infusion was reported to be effective for high-dose BZD detoxification, but there is concern about the risk of convulsions during this treatment. We evaluated the occurrence of seizures in 450 consecutive high-dose BZD dependence patients admitted to our unit from April 2012 to April 2016 for detoxification with low-dose slow subcutaneous infusion of flumazenil associated with routine anticonvulsant prophylaxis. In our sample, 22 patients (4.9%) reported history of convulsions when previously attempting BZD withdrawal. Only four patients (0.9%) had seizures during ( n = 2) or immediately after ( n = 2) flumazenil infusion. The two patients with seizures during flumazenil infusion were poly-drug misusers. The most common antiepileptic drugs (AEDs) used for anticonvulsant prophylaxis were either valproate 1000 mg or levetiracetam 1000 mg. Our data indicate that, when routinely associated with AEDs prophylaxis, low-dose slow subcutaneous flumazenil infusion represents a safe procedure, with low risk of seizure occurrence.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269881117714050DOI Listing

Publication Analysis

Top Keywords

flumazenil infusion
20
anticonvulsant prophylaxis
12
high-dose bzd
12
low-dose slow
12
low risk
8
slow flumazenil
8
routine anticonvulsant
8
high-dose benzodiazepine
8
bzd dependence
8
bzd withdrawal
8

Similar Publications

Comparison of remimazolam and sevoflurane for general anesthesia during transcatheter aortic valve implantation: a randomized trial.

Can J Anaesth

December 2024

Department of Anesthesiology and Critical Care Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Purpose: Safe perioperative management of patients undergoing transcatheter aortic valve implantation (TAVI) is crucial. Remimazolam is a newly developed short-acting benzodiazepine. We hypothesized that combining remimazolam and flumazenil would reduce emergence time compared with sevoflurane in patients undergoing general anesthesia for TAVI.

View Article and Find Full Text PDF

Age-Related Response to Remimazolam among Older Patients Undergoing Orthopedic Surgery: A Single-Center Prospective Observational Study.

Medicina (Kaunas)

October 2024

Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

: Remimazolam, an ultra-short-acting benzodiazepine, is increasingly used in procedural sedation and general anesthesia. It is characterized by rapid onset of action, inactive metabolites, no delay in recovery, and few adverse events. Its hemodynamic and respiratory stability are comparable to other anesthetics, and it is safe in high-risk and geriatric patients.

View Article and Find Full Text PDF
Article Synopsis
  • E2730 is a GABA transporter-1 inhibitor that shows significant anti-seizure effects in a rodent model of chronic temporal lobe epilepsy, specifically the kainic acid status epilepticus (KASE) rat model.
  • A randomized cross-over study revealed that E2730 treatment resulted in a notable reduction of spontaneous seizures, with 73% of the treated animals becoming seizure-free and alterations in various neuroimaging measures indicating changes in GABAergic function.
  • The study found that while E2730 lowered taurine levels and affected gamma frequency oscillations in the brain, it did not change GABA receptor affinity or density, highlighting its complex impact on brain neurotransmission during seizure management.
View Article and Find Full Text PDF
Article Synopsis
  • The study explores the impact of remimazolam, a new anesthetic, on motor-evoked potentials (MEPs) during general anesthesia in patients undergoing spinal fusion surgery.
  • Ten adult patients were monitored with varying doses of remimazolam to determine whether higher doses affected MEP amplitude.
  • Results indicated no significant difference in MEP amplitude after increasing the dose, suggesting remimazolam may have a minimal impact on these electrical signals in the brain.
View Article and Find Full Text PDF

Purpose: Remimazolam tosilate is a novel ultrafast-acting benzodiazepine that has a rapid emergence even after continuous infusion when using flumazenil. So far, relatively few articles are still focusing on the quality of recovery after general anesthesia with remimazolam, especially in day surgery. This study aimed to compare the early postoperative quality of recovery of remimazolam tosilate with flumazenil and propofol in patients undergoing day surgery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!